Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
Anna Z. Wec(Adimab (United States)), Laura M. Walker(Children's Hospital of Philadelphia), Elizabeth Champney(Adimab (United States)), Shu Lin(Dartmouth College), Sarat Pudi(Adimab (United States)), Longping V. Tse(Saint Louis University), John M. Dye(United States Army Medical Research Institute of Infectious Diseases), Ralph S. Baric(University of North Carolina at Chapel Hill), Barney S. Graham(National Institutes of Health), Ethan Laudermilch, Cecilia M. O’Brien(United States Army Medical Research Institute of Infectious Diseases), Robert H. Bortz, Irina Burnina(Adimab (United States)), Ariel S. Wirchnianski(Albert Einstein College of Medicine), Daniel Wrapp(Duke University), Daniel P. Maurer(Ragon Institute of MGH, MIT and Harvard), M. Eugenia Dieterle, Mrunal Sakharkar(Adimab (United States)), Andrew S. Herbert(United States Army Medical Research Institute of Infectious Diseases), Juergen H. Nett(Adimab (United States)), Catalina Florez(United States Military Academy), Dennis R. Burton(Scripps Research Institute), J. Maximilian Fels(Albert Einstein College of Medicine), James E. Voss(Scripps Research Institute), Rohit K. Jangra(Louisiana State University Health Sciences Center Shreveport), Nicole V. Johnson(The University of Texas at Austin), Nianshuang Wang(The University of Texas at Austin), Deli Huang(Scripps Research Institute), Melanie Sinclair(Adimab (United States)), Asparouh Lilov(Adimab (United States)), Kartik Chandran(Albert Einstein College of Medicine), David Nemazee(Scripps Research Institute), Ching‐Lin Hsieh(The University of Texas at Austin), Michael E. Brown(Adimab (United States)), Jason S. McLellan(The University of Texas at Austin), Carl Johnson(Adimab (United States)), Denise Haslwanter
Cited by 28
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
|Nature Communications|2020|1.8k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
|Science|2020|1.4k